These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16966000)

  • 1. Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer.
    Price RA; Hannoun-Levi JM; Horwitz E; Buyyounouski M; Ruth KJ; Ma CM; Pollack A
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):583-92. PubMed ID: 16966000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
    Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
    Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
    Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
    Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
    Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
    Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
    Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
    Ganswindt U; Paulsen F; Corvin S; Hundt I; Alber M; Frey B; Stenzl A; Bares R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):347-55. PubMed ID: 17236960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.
    Hille A; Töws N; Schmidberger H; Hess CF
    Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies.
    Georg P; Georg D; Hillbrand M; Kirisits C; Pötter R
    Radiother Oncol; 2006 Jul; 80(1):19-26. PubMed ID: 16766068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric comparison of combined intensity-modulated radiotherapy (IMRT) and proton therapy versus IMRT alone for pelvic and para-aortic radiotherapy in gynecologic malignancies.
    Milby AB; Both S; Ingram M; Lin LL
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e477-84. PubMed ID: 22177626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.
    Fiorino C; Alongi F; Perna L; Broggi S; Cattaneo GM; Cozzarini C; Di Muzio N; Fazio F; Calandrino R
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):29-35. PubMed ID: 19467803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
    Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
    Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: a radiation treatment planner's perspective.
    Parker W; Patrocinio H
    Can J Urol; 2005 Jun; 12 Suppl 2():48-52. PubMed ID: 16018834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
    Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-planning study of prostate cancer intensity-modulated radiotherapy with a Varian Clinac operated without a flattening filter.
    Vassiliev ON; Kry SF; Kuban DA; Salehpour M; Mohan R; Titt U
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1567-71. PubMed ID: 17544596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.